ESMO Open is the European Society for Medical Oncology’s online-only, peer-reviewed Open Access journal, dedicated to publishing high-quality medical research and educational content from all disciplines of oncology, with a focus on innovative clinical and translational cancer research.
ESMO Open是欧洲肿瘤内科学会的仅在线、同行评审的开放获取期刊，致力于发表来自肿瘤学所有学科的高质量医学研究和教育内容，重点关注创新性临床和转化性癌症研究。
Modulation of peripheral blood immune cells by early use of steroids and its association with clinical outcomes in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors
来源期刊：ESMO OpenDOI：10.1136/esmoopen-2018-000457
Tolerability of BRAF/MEK inhibitor combinations: adverse event evaluation and management
来源期刊：ESMO OpenDOI：10.1136/esmoopen-2019-000491
Knowledge and use of biosimilars in oncology: a survey by the European Society for Medical Oncology
来源期刊：ESMO OpenDOI：10.1136/esmoopen-2018-000460
How we treat patients with leptomeningeal metastases
来源期刊：ESMO OpenDOI：10.1136/esmoopen-2019-000507
Elevated CRP levels indicate poor progression-free and overall survival on cancer patients treated with PD-1 inhibitors
来源期刊：ESMO OpenDOI：10.1136/esmoopen-2019-000531
How I treat ALK-positive non-small cell lung cancer
来源期刊：ESMO OpenDOI：10.1136/esmoopen-2019-000524
How I treat metastatic triple-negative breast cancer
来源期刊：ESMO OpenDOI：10.1136/esmoopen-2019-000504
UNICANCER: French prospective cohort study of treatment-related chronic toxicity in women with localised breast cancer (CANTO)
来源期刊：ESMO OpenDOI：10.1136/esmoopen-2019-000562
Development of sodium fluoride PET response criteria for solid tumours (NAFCIST) in a clinical trial of radium-223 in osteosarcoma: from RECIST to PERCIST to NAFCIST
来源期刊：ESMO OpenDOI：10.1136/esmoopen-2018-000439
Targeted therapy in cervical cancer
来源期刊：ESMO OpenDOI：10.1136/esmoopen-2018-000462
Susceptible loci associated with autoimmune disease as potential biomarkers for checkpoint inhibitor-induced immune-related adverse events
来源期刊：ESMO OpenDOI：10.1136/esmoopen-2018-000472
From crizotinib to lorlatinib: continuous improvement in precision treatment of ALK-positive non-small cell lung cancer
来源期刊：ESMO OpenDOI：10.1136/esmoopen-2019-000548
Assessing molecular subtypes of gastric cancer: microsatellite unstable and Epstein-Barr virus subtypes. Methods for detection and clinical and pathological implications
来源期刊：ESMO OpenDOI：10.1136/esmoopen-2018-000470
Prospective analysis of 895 patients on a UK Genomics Review Board
来源期刊：ESMO OpenDOI：10.1136/esmoopen-2018-000469
Maximising clinical benefit with adequate patient management beyond the second line in mCRC
来源期刊：ESMO OpenDOI：10.1136/esmoopen-2019-000495
Ex vivo lung cancer spheroids resemble treatment response of a patient with NSCLC to chemotherapy and immunotherapy: case report and translational study
来源期刊：ESMO OpenDOI：10.1136/esmoopen-2019-000536
Flucelvax Tetra: a surface antigen, inactivated, influenza vaccine prepared in cell cultures
来源期刊：ESMO OpenDOI：10.1136/esmoopen-2018-000481
How I treat MSI cancers with advanced disease
来源期刊：ESMO OpenDOI：10.1136/esmoopen-2019-000511
B7x—from bench to bedside
来源期刊：ESMO OpenDOI：10.1136/esmoopen-2019-000554
Changes in Recurrence Score by neoadjuvant endocrine therapy of breast cancer and their prognostic implication
来源期刊：ESMO OpenDOI：10.1136/esmoopen-2018-000476
How I treat cancer: treatment of rheumatological side effects of immunotherapy
来源期刊：ESMO OpenDOI：10.1136/esmoopen-2019-000529
How I treat gastric adenocarcinoma
来源期刊：ESMO OpenDOI：10.1136/esmoopen-2019-000521
New emerging targets in cancer immunotherapy beyond CTLA-4, PD-1 and PD-L1: Introducing an “ESMO Open – Cancer Horizons” Series
来源期刊：ESMO OpenDOI：10.1136/esmoopen-2019-000501
European Medicines Agency review of ixazomib (Ninlaro) for the treatment of adult patients with multiple myeloma who have received at least one prior therapy
来源期刊：ESMO OpenDOI：10.1136/esmoopen-2019-000570
Importance of genetic screens in precision oncology
来源期刊：ESMO OpenDOI：10.1136/esmoopen-2019-000505
Clinical insights on outcomes of corticosteroid administration in immune checkpoint inhibitor-induced pneumonitis by retrospective case series analysis
来源期刊：ESMO OpenDOI：10.1136/esmoopen-2019-000575
Screening tool for malignant bowel obstruction in relapsed, metastatic ovarian cancer
来源期刊：ESMO OpenDOI：10.1136/esmoopen-2018-000463
Olaratumab administered in two cases of phyllodes tumour of the breast: end of the beginning?
来源期刊：ESMO OpenDOI：10.1136/esmoopen-2018-000479
Exploratory analyses of consensus molecular subtype-dependent associations of TP53 mutations with immunomodulation and prognosis in colorectal cancer
来源期刊：ESMO OpenDOI：10.1136/esmoopen-2019-000523
What is new on the horizon in melanoma brain metastasis?
来源期刊：ESMO OpenDOI：10.1136/esmoopen-2019-000579
Variations in the management of diarrhoea induced by cancer therapy: results from an international, cross-sectional survey among European oncologists
来源期刊：ESMO OpenDOI：10.1136/esmoopen-2019-000607
Awareness of predatory journals and open access among medical oncologists: results of an online survey
来源期刊：ESMO OpenDOI：10.1136/esmoopen-2019-000580
Neoadjuvant treatment for intermediate/high-risk HER2-positive and triple-negative breast cancers: no longer an ‘option’ but an ethical obligation
来源期刊：ESMO OpenDOI：10.1136/esmoopen-2019-000515
Liquid biopsy assessment of synchronous malignancies: a case report and review of the literature
来源期刊：ESMO OpenDOI：10.1136/esmoopen-2019-000528
How I treat squamous ENT cancer
来源期刊：ESMO OpenDOI：10.1136/esmoopen-2019-000542
Expanding the TNM for cancers of the colon and rectum using machine learning: a demonstration
来源期刊：ESMO OpenDOI：10.1136/esmoopen-2019-000518
Targeting prognostic proinflammatory biomarkers to improve outcome on IO drugs
来源期刊：ESMO OpenDOI：10.1136/esmoopen-2019-000557
Factors associated with treatment delay in women with primary breast cancer who were referred to reproductive specialists
来源期刊：ESMO OpenDOI：10.1136/esmoopen-2018-000459
Care of adolescents and young adults with cancer in Asia: results of an ESMO/SIOPE/SIOP Asia survey
来源期刊：ESMO OpenDOI：10.1136/esmoopen-2018-000467
How I treat cancer special issue
来源期刊：ESMO OpenDOI：10.1136/ESMOOPEN-2019-000514
Cyclin D1 differential activation and its prognostic impact in patients with advanced breast cancer treated with trastuzumab
来源期刊：ESMO OpenDOI：10.1136/esmoopen-2018-000441
Rationale and design of the BRAVERY study (EPOC1701): a multicentre phase II study of eribulin in patients with BRAF V600E mutant metastatic colorectal cancer
来源期刊：ESMO OpenDOI：10.1136/esmoopen-2019-000590
Impact of tumour growth rate during preceding treatment on tumour response to regorafenib or trifluridine/tipiracil in refractory metastatic colorectal cancer
来源期刊：ESMO OpenDOI：10.1136/esmoopen-2019-000584
Desmoid tumours: a perfect example for making progress in treatment management through international collaboration
来源期刊：ESMO OpenDOI：10.1136/esmoopen-2019-000636
European Medicines Agency review of midostaurin (Rydapt) for the treatment of adult patients with acute myeloid leukaemia and systemic mastocytosis
来源期刊：ESMO OpenDOI：10.1136/esmoopen-2019-000606
Educational needs in gastrointestinal cancer: a consensus position paper from the ESMO Gastrointestinal Cancer Faculty
来源期刊：ESMO OpenDOI：10.1136/esmoopen-2019-000533
Prognosis of early stage small cell bladder cancer is not always dismal
来源期刊：ESMO OpenDOI：10.1136/esmoopen-2019-000559
Correction: Sequential HER2 blockade as effective therapy in chemorefractory, HER2 gene-amplified, RAS wild-type, metastatic colorectal cancer: learning from a clinical case
来源期刊：ESMO OpenDOI：10.1136/esmoopen-2017-000299corr1
Contrasting evidence to reimbursement reality for off-label use (OLU) of drug treatments in cancer care: rationale and design of the CEIT-OLU project
来源期刊：ESMO OpenDOI：10.1136/esmoopen-2019-000596
How I treat NTRK gene fusion-positive cancers
来源期刊：ESMO OpenDOI：10.1136/esmoopen-2019-000612
